



21st International Society of Hypertension
Clinical Science Young Investigator Award
Fukuoka, Japan, 2006

Review Articles:

1. **Watanabe T**, Watanabe-Kominato K, Takahashi Y, Kojima M, Watanabe R. Adipose tissue-derived omentin-1 function and regulation. *Compr Physiol* 2017;7:765-781.
2. **Watanabe T**, Konii H, Sato K, Itoh F. The roles of novel vasoactive agents in atherosclerotic cardiovascular diseases: good or bad guys? *Cardiovascular Disease I* 2014, 117-132.
3. Sato K, Watanabe R, Itoh F, Shichiri M, **Watanabe T**. Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases. *Int J Hypertens* 2013;2013:965140.
4. **Watanabe T**, Sato K, Itoh F, Noguchi Y, Fujimoto K, Koyama T, Shichiri M. Emerging roles for vasoactive peptides in diagnostic and therapeutic strategies against atherosclerotic cardiovascular diseases. *Curr Protein Pept Sci* 2013;14:472-480.
5. **Watanabe T**, Sato K, Itoh F, Wakabayashi K, Shichiri M, Hirano T. Endogenous bioactive peptides as biomarkers for atherosclerotic coronary heart disease. *Sensors (Basel)* 2012;12:4974-4985.
6. **Watanabe T**, Koba S. Roles of serotonin in atherothrombosis and related disease. *Traditional and Novel Risk Factors in Atherothrombosis* 2012, 57-70.
7. Shichiri M, Izumiyama H, **Watanabe T**. Salusins. *Handbook of Biologically Active Peptides*

8. Wakabayashi K, Pakala R, **Watanabe T**, Mori H, Iso Y, Suzuki H. Novel technologies and future perspectives of drug-eluting stent. *Translational Medicine* 2012, S7-002, doi: 10.4172/2161-1025.S7-002.
9. Iso Y, **Watanabe T**, Shoji M, Suzuki H. Stem/progenitor-cell-based approach for restenosis after percutaneous coronary intervention: Application of bone marrow progenitors and future perspectives. *Translational Medicine* 2012, S7-001, doi: 10.4172/2161-1025.S7-001.
10. **Watanabe T**, Sato K, Itoh F, Iso Y. Pathogenic involvement of heregulin- β_1 in anti-atherogenesis. *Regul Peptides* 2012;175:11-14.
11. **Watanabe T**, Sato K, Itoh F, Iso Y, Nagashima M, Hirano T, Shichiri M. The roles of salusins in atherosclerosis and related cardiovascular diseases. *J Am Soc Hypertens* 2011;5:359-365.
12. **Watanabe T**, Arita S, Shiraishi Y, Suguro T, Sakai T, Hongo S, Miyazaki A. Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases. *Curr Med Chem* 2009;16:550-563.
13. **Watanabe T**. Urotensin II promotes atherosclerosis. *Seikagaku* 2008;80:40-44.
14. **Watanabe T**, Kanome T, Miyazaki A. Relationship between hypertension and atherosclerosis: from a viewpoint of the most potent vasoconstrictor human urotensin II. *Curr Hypertens Rev* 2006;2:237-246.
15. **Watanabe T**, Kanome T, Miyazaki A, Katagiri T. Human urotensin II as a link between hypertension and coronary artery disease. *Hypertens Res* 2006;29:375-387.
16. **Watanabe T**, Kanome T, Suguro T, Miyazaki A. Human urotensin II and metabolic syndrome. *Vasc Dis Prev* 2006;3:91-98.
17. Miyazaki A, Kanome T, **Watanabe T**. Inhibitors of acyl-coenzyme A:cholesterol acyltransferase. *Curr Drug Targets Cardiovasc Haematol Disord* 2005;5:463-469.
18. **Watanabe T**, Miyazaki A. Roles of vasoactive agents in macrophage foam cell formation and atherosclerosis. In Miyazaki A, Imawari M (eds): *Lifestyle-related diseases*. Springer 2007, p.89-96.
19. Hongo S, **Watanabe T**, Takahashi K, Miyazaki A. Acceleration of foam cell formation by leptin in human monocyte-derived macrophages. In Miyazaki A, Imawari M (eds): *Lifestyle-related diseases*. Springer 2007, p. 155-158.
20. Miyazaki A, **Watanabe T**. Acyl-coenzyme A: cholesterol acyltransferase (ACAT). *Nippon Rinsho* 2004;62 Suppl 12:89-91.
21. **Watanabe T**, Akutsu Y, Katagiri T, Michihata T, Okazaki O, Harumi K. Assessment of myocardial viability with electrocardiographic ST-segment changes induced by low-level exercise. *Electrocardiology '97*, 1998, p. 311-315.

Original Articles:

1. Shirai R, Sato K*, Yamashita T, Yamaguchi M, Okano T, Watanabe-Kominato K, Watanabe R, Matsuyama T, Ishibashi-Ueda H, Koba S, Kobayashi Y, Hirano T, **Watanabe T**. Neopterin counters vascular inflammation and atherosclerosis. *J Am Heart Assoc* 2008, in press.
2. Kojima M, Ozawa N, Mori Y, Takahashi Y, Watanabe-Kominato K, Shirai R, Watanabe R, Sato K, Matsuyama T, Ishibashi-Ueda H, Koba S, Kobayashi Y, Hirano T, **Watanabe T**. Catestatin prevents macrophage-driven atherosclerosis but not arterial injury-induced neointimal hyperplasia. *Thromb Haemost* 2018, in press.
3. Terasaki M, Hiromura M, Mori Y, Kohashi K, Kushima H, Ohara M, **Watanabe T**, Andersson O, Hirano T. Combination therapy with a sodium-glucose cotransporter 2 inhibitor and a dipeptidyl peptidase-4 inhibitor synergistically suppresses macrophage foam cell formation and atherosclerosis in diabetic mice. *Int J Endocrinol* 2017;2017:1365209.
4. Sato K, Shirai R, Hontani M, Shinooka R, Hasegawa A, Kichise T, Yamashita T, Yoshizawa H, Watanabe R, Matsuyama T, Ishibashi-Ueda H, Koba S, Kobayashi Y, Hirano T, **Watanabe T**. A potent vasoconstrictor kisspeptin-10 induces atherosclerotic plaque progression and instability: reversal by its receptor GPR54 antagonist. *J Am Heart Assoc* 2017;6:e005790.
5. Watanabe R, Watanabe H, Takahashi Y, Kojima M, Konii H, Watanabe K, Shirai R, Sato K, Matsuyama T, Ishibashi-Ueda H, Iso Y, Koba S, Kobayashi Y, Hirano T, **Watanabe T**. Atheroprotective Effects of Tumor Necrosis Factor-Stimulated Gene-6. *JACC Basic Transl Sci* 2016;6:494–509.
6. Hiromura M, Mori Y, Kohashi K, Terasaki M, Shinmura K, Negoro T, Kawashima H, Kogure M, Wachi T, Watanabe R, Sato K, Kushima H, Tomoyasu M, Nakano Y, Yamada Y, **Watanabe T**, Hirano T. Suppressive effects of glucose-dependent insulinotropic polypeptide on cardiac hypertrophy and fibrosis in angiotensin II-infused mouse models. *Circ J* 2016;80:1988-97.
7. Yamamoto K, Tajima Y, Hasegawa A, Takahashi Y, Kojima M, Watanabe R, Sato K, Shichiri M, **Watanabe T**. Contrasting effects of stanniocalcin-related polypeptides on macrophage foam cell formation and vascular smooth muscle cell migration. *Peptides* 2016;82:120-127.
8. Naito C, Hashimoto M, Watanabe K, Shirai R, Takahashi Y, Kojima M, Watanabe R, Sato K, Iso Y, Matsuyama T, Suzuki H, Ishibashi-Ueda H, **Watanabe T**. Facilitatory effects of fetuin-A on atherosclerosis. *Atherosclerosis* 2016;246:344-351.
9. Watanabe K, Watanabe R, Konii H, Shirai R, Sato K, Matsuyama T, Ishibashi-Ueda H, Koba S, Kobayashi Y, Hirano T, **Watanabe T**. Counteractive effects of omentin-1 against atherogenesis. *Cardiovasc Res* 2016;110:118-128.
10. Kohashi K, Hiromura M, Mori Y, Terasaki M, **Watanabe T**, Kushima H, Shinmura K, Tomoyasu M, Nagashima M, Hirano T. A dipeptidyl peptidase-4 inhibitor but not incretins suppresses abdominal aortic aneurysms in angiotensin II-infused apolipoprotein E-null mice. *J Atheroscler Thromb* 2016;23:441-454.
11. Terasaki M, Hiromura M, Mori Y, Kohashi K, Nagashima M, Kushima H, **Watanabe T**, Hirano T. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. *PLOS ONE* 2015;10:e0143396.
12. Furuta C, Miyamoto T, Takagi T, Noguchi Y, Kaneko J, Itoh S, **Watanabe T**, Itoh F. Transforming growth factor- β signaling enhancement by long-term exposure to hypoxia in a tumor microenvironment composed of Lewis lung carcinoma cells. *Cancer Sci* 2015;106:1524-1533.

13. Hasegawa A, Sato K, Shirai R, Watanabe R, Yamamoto K, Watanabe K, Nohtomi K, Hirano T, **Watanabe T**. Vasoprotective effects of urocortin 1 against atherosclerosis *in vitro* and *in vivo*. PLOS ONE 2014;9:e110866.
14. Mori S, Yamada H, Noguchi Y, Miyakawa T, Morikawa R, **Watanabe T**, Takasu M. Structure analysis of GLP-1 in DPC micelle. Peptide Science 2015:213-216.
15. Mori S, Yamada H, Fukuda M, Fukasawa Y, Miyakawa T, Morikawa R, **Watanabe T**, Takasu M. Structure analysis of glucagon-like peptide-1 by molecular dynamics simulation. Peptide Science 2013:285-288.
16. Tashiro Y, Sato K, **Watanabe T**, Nohtomi K, Terasaki M, Nagashima M, Hirano T. A glucagon-like polypeptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides 2014;54C:19-26.
17. Usui S, Iso Y, Sasai M, Mizukami T, Mori H, **Watanabe T**, Shioda S, Suzuki H. Kisspeptin-10 induces endothelial senescence and impaired endothelial growth. Clin Sci 2014;127:47-55.
18. Fujimoto K, Hayashi A, Kamata Y, Ogawa A, Ichikawa R, **Watanabe T**, Iso Y, Koba S, Kobayashi S, Koyama T, Shichiri M. Circulating levels of human salusin- β , a potent hemodynamic and atherogenesis regulator. PLoS One 2013;8:e76714.
19. Konii H, Sato K, Kikuchi S, Okiyama H, Watanabe R, Hasegawa A, Yamamoto K, Itoh F, Hirano T, **Watanabe T**. Stimulatory effects of cardiotrophin-1 on atherosclerosis. Hypertension 2013;62:942-950.
20. Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, Nogi Y, Katayama Y, Sato K, Itoh F, **Watanabe T**, Hirano T. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. PLoS One 2013;8:e70933
21. Itoh F, Itoh S, Adachi T, Ichikawa K, Matsumura Y, Takagi T, Festing M, **Watanabe T**, Weinstein M, Karlsson S, Kato M. Smad2/Smad3 in endothelium is indispensable for vascular stability via S1PR1 and N-cadherin expressions. Blood 2012;119:5320-5328.
22. Nogi Y, Nagashima M, Terasaki M, Nohtomi K, **Watanabe T**, Hirano T. Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS One 2012;7:e35683.
23. Koya T, Miyazaki T, **Watanabe T**, Shichiri M, Atsumi T, Kim-Kaneyama J, Miyazaki A. Salusin- β accelerates inflammatory responses in vascular endothelial cells via NF- κ B signaling in LDL receptor-deficient mice *in vivo* and HUVECs *in vitro*. Am J Physiol Heart Circ Physiol 2012;303:H96-H105.
24. Terasaki M, Nagashima M, **Watanabe T**, Miyazaki A, Hirano T. Preventive effects of dipeptidyl peptidase-4 inhibitor on the development of atherosclerotic lesions in apolipoprotein E-null mice. Metabolism 2012;61:974-977.
25. Kodate S*, **Watanabe T***, Yokoe T, Watanabe Y, Tazaki T, Tanaka A, Yamamoto M, Ohta S, Suguro T, Hirano T, Adachi M, Minoguchi K. Plasma levels of urotensin II are elevated in obstructive sleep apnea. Chest 2011, in review.
26. Nagashima M,* **Watanabe T***, Terasaki M, Tomoyasu M, Nohtomi K, Kim-Kaneyama J, Miyazaki A, Hirano T. Native incretins and related agents prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 2011;54:2649-2659.

27. Yoshinaka Y, Shibata H, Kobayashi H, Kuriyama H, Shibuya K, Tanabe S, **Watanabe T**, Miyazaki A. A selective ACAT-1 inhibitor, K-604, stimulates collagen production in cultured smooth muscle cells and alters plaque phenotype in apolipoprotein E-knockout mice. *Atherosclerosis* 2010;213:85-91.
28. Hirano T, Nohtomi K, Nakanishi N, **Watanabe T**, Hyodo T, Taira T. Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. *Clin Nephrol* 2010;74:282-287.
29. Yamagata B, **Watanabe T**, Tomioka H, Kobayashi H, Nakano Y, Mimura M. Preliminary use of insulin-like growth factor-I as a biomarker for sorting out high-dose donepezil responders in Japanese patients with Alzheimer's disease. *Regul Peptides* 2010;163:137-142.
30. Kimoto S, Sato K, **Watanabe T**, Suguro T, Koyama T, Shichiri M. Serum levels and urinary excretion of salusin- α in renal insufficiency. *Regul Peptides* 2010;162:129-132.
31. Nagashima M, **Watanabe T**, Shichiri M, Sato K, Shiraishi Y, Morita R, Terasaki M, Arita S, Hongo S, Miyazaki A, Hirano T. Chronic infusion of salusin- α and - β exerts opposite effects on macrophage foam cell formation and atherosclerosis in apolipoprotein E-deficient mice. *Atherosclerosis* 2010;212:70-77.
32. Xu G,* **Watanabe T**,* Iso Y, Koba S, Sakai T, Nagashima M, Arita S, Hongo S, Ota H, Kobayashi Y, Miyazaki A, Hirano T. Preventive effects of heregulin- β_1 on macrophage foam cell formation and atherosclerosis. *Circ Res* 2009;105:500-510.
33. Hori M, **Watanabe T**, Miyazaki A. Characterization of foam cell formation in human and mouse macrophages. *J Lipid Res* 2010, in preparation.
34. Ban Y, **Watanabe T**, Suguro T, Miyazaki A, Matsuyama T, Iso Y, Sakai T, Ota H, Idei T, Kato N, Nakano Y, Sato R, Ban Y, Kobayashi Y. Increased plasma human urotensin II levels and carotid atherosclerosis are associated with vascular dementia. *J Atheroscler Thromb* 2009;16:179-187.
35. Hongo S, **Watanabe T**, Kanome T, Kageyama H, Shioda S, Miyazaki A. Leptin modulates ACAT-1 expression and cholesterol efflux from human macrophages. *Am J Physiol Endocrinol Metab* 2009;297:474-482.
36. Kanome T, **Watanabe T**, Nishio K, Takahashi K, Hongo S, Miyazaki A. Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II type 1 receptor in human monocyte-macrophages. *Hypertens Res* 2008;31:1801-1810.
37. Shiraishi Y, **Watanabe T**, Suguro T, Nagashima M, Kato R, Hongo S, Itabe H, Miyazaki A, Hirano T, Adachi M. Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice. *J Hypertens* 2008;26:1955-1965.
38. Suguro T, **Watanabe T**, Kodate S, Xu G, Hirano T, Adachi M, Miyazaki A. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. *Clin Sci (Lond)* 2008;115:327-334.
39. **Watanabe T**, Suguro T, Sato K, Koyama T, Nagashima M, Kodate S, Hirano T, Adachi M, Shichiri M, Miyazaki A. Serum salusin- α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. *Hypertens Res* 2008;31:463-468.
40. **Watanabe T**, Nishio K, Kanome T, Matsuyama T, Koba S, Sakai T, Sato K, Hongo S, Nose K, Ota H, Kobayashi Y, Katagiri T, Shichiri M, Miyazaki A. Impact of salusin- α and - β on human

- macrophage foam cell formation and coronary atherosclerosis. *Circulation* 2008;117:638-648.
41. Tei E, **Watanabe T**, Yamamoto H, Miyazaki A, Nakadate T, Kato N, Mimura M. Use of serum insulin-like growth factor-1 levels to predict psychiatric non-response to donepezil in patients with Alzheimer's disease. *Growth Horm IGF Res* 2008;18:47-54.
 42. Ban Y, **Watanabe T**, Miyazaki A, Idei T, Iguchi T, Katagiri T. Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. *Atherosclerosis* 2007;195:153-159.
 43. **Watanabe T**, Takahashi K, Kanome T, Hongo S, Koba S, Katagiri T, Miyazaki A, Pakala R, Benedict CR. Human urotensin-II potentiates mildly oxidized LDL-induced vascular smooth muscle cell proliferation: Comparison with other vasoactive agents and hydrogen peroxide. *Hypertens Res* 2006;29:821-831.
 44. Suguro T, **Watanabe T**, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. *Am J Hypertens* 2007;20:211-217.
 45. Ikenoya M, Yoshinaka Y, Kobayashi H, Kawamine K, Shibuya K, Sato F, Sawanobori K, **Watanabe T**, Miyazaki A. A selective ACAT-1 inhibitor, K-604, suppress fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. *Atherosclerosis* 2007;191:290-297.
 46. Hongo S, **Watanabe T**, Takahashi K, Miyazaki A. Ndr4 enhances NGF-induced ERK activation uncoupled with Elk-1 activation. *J Cell Biochem* 2006;98:185-193.
 47. Suguro T, **Watanabe T**, Kanome T, Kodate S, Hirano T, Miyazaki A, Adachi M. Serotonin acts as an up-regulator of acyl-coenzyme A:cholesterol acyltransferase-1 in human monocyte-macrophages. *Atherosclerosis* 2006;186:275-281.
 48. **Watanabe T**, Suguro T, Kanome T, Sakamoto Y, Kodate S, Hagiwara T, Hongo S, Hirano T, Adachi M, Miyazaki A. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. *Hypertension* 2005;46:738-744.
 49. **Watanabe T**, Miyazaki A, Yamamoto H, Idei T, Iguchi T, Katagiri T. Relation of serum insulin-like growth factor-1 levels to Alzheimer's disease and vascular dementia. *J Am Geriatr Soc* 2005;53:1748-1753.
 50. Yamamoto H, **Watanabe T**, Miyazaki A, Katagiri T, Idei T, Iguchi T, Mimura M, Kamijima K. High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia. *J Am Geriatr Soc* 2005;53:583-589.
 51. **Watanabe T**, Yamamoto H, Idei T, Iguchi T, Katagiri T. Influence of insulin-like growth factor-I and hepatocyte growth factor on carotid atherosclerosis and cognitive function in the elderly. *Dement Geriatr Cogn Disord* 2004;18:67-74.
 52. **Watanabe T**, Koba S, Kawamura M, Itokawa M, Idei T, Nakagawa Y, Iguchi T, Katagiri T. Small dense low-density lipoprotein and carotid atherosclerosis in relation to vascular dementia. *Metabolism* 2004;53:476-482.
 53. **Watanabe T**, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. *Am J Hypertens* 2003;16:754-760.
 54. Pakala R, **Watanabe T**, Benedict CR. Induction of endothelial cell proliferation by angiogenic

- factors released by activated monocytes. *Cardiovasc Radiat Med (Cardiovasc Revasc Med)* 2002;3:95-101.
55. **Watanabe T**, Koba S, Katagiri T, Pakala R, Benedict CR. Lysophosphatidylcholine potentiates the mitogenic effect of various vasoactive compounds on rabbit aortic smooth muscle cells. *Jpn Heart J (Int Heart J)* 2002;43:409-416.
 56. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells. *Hypertens Res* 2002;25:311-314.
 57. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Oxidized low-density lipoproteins potentiate the mitogenic effect of 5-hydroxytryptamine on vascular smooth muscle cells. *Jpn Heart J (Int Heart J)* 2002;43:35-42.
 58. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Lysophosphatidylcholine is a major contributor to the synergistic effect of mildly oxidized LDL with endothelin-1 on vascular smooth muscle cell proliferation. *J Cardiovasc Pharmacol* 2002;39:449-459.
 59. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Serotonin potentiates angiotensin II-induced vascular smooth muscle cell proliferation. *Atherosclerosis* 2001;159:269-279.
 60. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. *J Hypertens* 2001;19:2191-2196.
 61. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. *J Vasc Res* 2001;38:341-349.
 62. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. *Circulation* 2001;104:16-18.
 63. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. *J Hypertens* 2001;19:1065-1073.
 64. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Angiotensin II and serotonin potentiate endothelin-1-induced vascular smooth muscle cell proliferation. *J Hypertens* 2001;19:731-739.
 65. **Watanabe T**, Pakala R, Koba S, Katagiri T, Benedict CR. Lysophosphatidylcholine and reactive oxygen species mediate the synergistic effect of mildly oxidized LDL with serotonin on vascular smooth muscle cell proliferation. *Circulation* 2001;103:1440-1445.
 66. **Watanabe T**, Pakala R, Katagiri T, Benedict CR. Lipid peroxidation product 4-hydroxy-2-nonenal acts synergistically with serotonin in inducing vascular smooth muscle cell proliferation. *Atherosclerosis* 2001;155:37-44.
 67. Koba S, Pakala R, **Watanabe T**, Katagiri T, Benedict CR. Synergistic interaction between thromboxane A₂ and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. *Prostaglandins Leukot Essent Fatty Acids* 2000;63:329-335.
 68. **Watanabe T**, Okazaki O, Izumo K, Michihata T, Katagiri T, Harumi K. Brady-tachycardia syndrome after radiotherapy for lung cancer: assessment by computed tomography and carbon-11 methionine positron emission tomography. *Jpn Heart J (Int Heart J)* 1999;40:677-681.
 69. **Watanabe T**, Michihata T, Yamanaka H, Akutsu Y, Okazaki O, Katagiri T, Harumi K. Exercise-

- induced QTc-interval changes for predicting improvement in regional blood flow in ischemic myocardium and cardiac output after coronary angioplasty in patients with right bundle-branch block. *Clin Cardiol* 2000;23:359-364.
70. **Watanabe T**, Akutsu Y, Yamanaka H, Okazaki O, Michihata T, Katagiri T, Harumi K. Exercise-induced ST-segment depression: imbalance between myocardial oxygen demand and myocardial blood flow. *Acta Cardiol* 2000;55:25-31.
 71. Koba S, **Watanabe T**, Iso Y, Shibata M, Yorozyu M, Nakatani M, Suzuki H, Geshi E, Katagiri T. Interaction between thromboxine A₂ and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. *Cardiac Structure and Metabolism* 1999;22:123-127.
 72. **Watanabe T**, Okazaki O, Izumo K, Katagiri T, Harumi K. Evaluation of appropriate pacing with myocardial perfusion and cardiac function as a treatment of end-stage idiopathic dilated cardiomyopathy. *Pacing Clin Electrophysiol (PACE)* 1999;22:1844-1845.
 73. Koba S, Pakala R, **Watanabe T**, Katagiri T, Benedict CR. Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins. *J Am Coll Cardiol (JACC)* 1999;34:1644-1651.
 74. Arata Y, Iijima K, **Watanabe T**, Aoki S, Nomizo A, Nishi T, Geshi E, Katagiri T. Alternations of angiotensin II type 1 receptor gene expression in SHR hearts. *Cardiac Structure and Metabolism* 1998;20:321-326.
 75. **Watanabe T**, Kikushima S, Tanno K, Geshi E, Kobayashi Y, Takeyama Y, Katagiri T. Uncommon electrocardiographic changes corresponding to symptoms during recurrent pulmonary embolism as documented by computed tomography scans. *Clin Cardiol* 1998;21:858-861.
 76. **Watanabe T**, Harumi K, Akutsu Y, Yamanaka H, Okazaki O, Michihata T, Katagiri T. Correlation between exercise-induced ischemic ST-segment depression and myocardial blood flow quantified by positron emission tomography. *Am Heart J* 1998;136:533-542.
 77. **Watanabe T**, Okazaki O, Akutsu Y, Yamanaka H, Michihata T, Katagiri T, Harumi K. Correlation between myocardial blood flow and fasting glucose metabolism in ischemic heart disease: quantitative assessment by nitrogen-13 ammonia and fluorine-18 fluorodeoxyglucose positron emission tomography. *Jpn Heart J (Int Heart J)* 1998;39:275-285.
 78. **Watanabe T**, Harumi K, Michihata T, Okazaki O, Yamanaka H, Akutsu Y, Katagiri T. Exercise-induced ST-segment changes permit prediction of improvement in left ventricular ischemic dysfunction after revascularization: evaluation with positron emission tomographic measurements of regional myocardial blood flow and cardiac output. *J Nucl Cardiol* 1998;5:256-264.
 79. Akutsu Y, Shinozuka A, Huang TY, **Watanabe T**, Yamada T, Yamanaka H, Saitoh T, Geshi E, Takenaka H, Takeyama Y, Munechika H, Ban Y, Katagiri T. Hypertrophic cardiomyopathy with idiopathic apical left ventricular aneurysm. *Jpn Circ J (Circ J)* 1998;62:127-131.
 80. **Watanabe T**, Harumi K, Akutsu Y, Yamanaka H, Michihata T, Okazaki O, Katagiri T. Relation between exercise-induced myocardial ischemia as assessed by nitrogen-13 ammonia positron emission tomography and QT interval behavior in patients with right bundle branch block. *Am J Cardiol* 1998;81:816-821.
 81. **Watanabe T**, Yanagishita T, Konno N, Geshi E, Katagiri T. Reversal of early metabolic dysfunction in hypertensive rat left-ventricular myocytes by angiotensin-converting enzyme inhibition. *Jpn Heart J (Int Heart J)* 1997;38:503-514.

82. Akutsu Y, Harumi K, Michihata T, **Watanabe T**, Yamanaka H, Okazaki O, Kashida M, Hasegawa M, Katagiri T. Correlations between resting regional wall motion and regional myocardial blood flow (at rest and during exercise) in infarcted-related myocardium: a study with ¹³N-ammonia positron emission tomography. *Jpn Circ J (Circ J)* 1997;61:665-672.
83. **Watanabe T**, Harumi K, Akutsu Y, Yamanaka H, Okazaki O, Michihata T, Katagiri T. Significance of downsloping ST-segment depression induced by low-level exercise in severe coronary artery disease: assessment with myocardial ischemia and collateral perfusion. *Jpn Heart J (Int Heart J)* 1997;38:207-218.
84. Iijima K, Geshi E, Arata Y, **Watanabe T**, Iwata T, Arata H, Ishioka H, Umetsu K, Konno N, Katagiri T. Attenuation with ACE-I (Alacepril) on the stunned myocardium. *Cardiac Structure and Metabolism* 1996;18:147 -154.
85. Akutsu Y, Hara T, Michihata T, **Watanabe T**, Yamanaka H, Okazaki O, Kashida M, Hasegawa M, Harumi K, Katagiri T. Functional role of coronary collaterals with exercise in infarct-related myocardium. *Int J Cardiol* 1995;51:47-55.
86. Yamanaka H, Akutsu Y, **Watanabe T**, Okazaki O, Michihata T, Hasegawa M, Hara T, Katagiri T, Harumi K. Relation between cardiac index and regional myocardial blood flow in the non-infarcted wall using PET with ¹³NH₃ in healed myocardial infarction. *Jpn Heart J (Int Heart J)* 1995;36:283-292.
87. Iwata T, Mukae S, **Watanabe T**, Ishioka H, Itoh S, Umetsu K, Geshi E, Konno N, Yanagishita T, Katagiri T. Effects of catecholamine and amrinone on the metabolism of noninfarcted myocardium in cardiogenic shock. *Mechanisms of Heart Failure* 1995, p. 401-410.
88. Ishioka H, Geshi E, **Watanabe T**, Iwata T, Itoh S, Mukae S, Mochizuki M, Umetsu K, Konno N, Yanagishita T, Katagiri T. Metabolic changes in nonischemic myocardium during pump failure. *Mechanisms of Heart Failure* 1995, p. 63-74.
89. **Watanabe T**, Konno N, Iijima K, Makishima N, Nakatani M, Iwata T, Arata H, Ishioka H, Umetsu K, Geshi E, Yanagishita T, Katagiri T. Altered metabolism in cardiac myocytes isolated from the spontaneously hypertensive rat. *Cardiac Structure and Metabolism* 1994;16:395-400.
90. Akutsu Y, Hara T, **Watanabe T**, Yamanaka H, Okazaki O, Kashida M, Michihata T, Hasegawa M, Harumi K, Katagiri T. Determination of regional myocardial blood flow with ¹³N-ammonia positron emission tomography during low-grade exercise for evaluating coronary artery stenosis. *Jpn Circ J (Circ J)* 1994;58:303-314.
91. Geshi E, Ishioka H, **Watanabe T**, Iwata T, Arata H, Konno N, Yanagishita T, Katagiri T. Effect of nicorandil on ischemic preconditioning. *Ther Res* 1994;15:53-61.
92. Okazaki O, Michihata T, Kobayashi S, Kume M, Kashima T, **Watanabe T**, Yamanaka H, Akutsu Y, Serizawa S, Hara T, Harumi K. Low-grade exercise induced ischemic ST depression and regional myocardial blood flow determined by PET using N-13 ammonia. *Bulletin of the PFRI* 1993;83:9-18.
93. Ban Y, **Watanabe T**, Miyazaki A, Idei T, Kato N, Ban Y, Kobayashi Y, Hirano T. Effect of pitavastatin on cognitive function in patients with Alzheimer disease. *Ther Res* 2008;29:1171-1174.

Others

